193481-78-6

Basic information

• Product Name: 3-aMino-5-chloro-2-nitrobenzoic acid
• Synonyms: 3-aMino-5-chloro-2-nitrobenzoic acid
• CAS NO: 193481-78-6
• Molecular Formula: C₇H₅ClN₂O₄
• Molecular Weight: 216.5786
• EINECS: -0
• Mol File: 193481-78-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-aMino-5-chloro-2-nitrobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-aMino-5-chloro-2-nitrobenzoic acid(193481-78-6)
• EPA Substance Registry System: 3-aMino-5-chloro-2-nitrobenzoic acid(193481-78-6)

Safety Data

• Hazardous Substances Data: 193481-78-6(Hazardous Substances Data)

Upstream product

• 2516-95-2 5-chloro-2-nitrobenzoic acid 

Downstream Products

• 1372540-55-0 1-[(3-chloro-2-methylphenyl)methyl]-6-(4-morpholinyl)-4-(4H-1,2,4-triazol-3-yl)-2-(trifluoromethyl)-1H-benzimidazole 
• 1372540-53-8 1-[(2,3-dichlorophenyl)methyl]-6-(4-morpholinyl)-4-(4H-1,2,4-triazol-3-yl)-2-(trifluoromethyl)-1H-benzimidazole 
• 1372540-32-3 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzimidazole 
• 1372540-34-5 C₂₂H₂₁ClF₃N₃O₂ 
• 1372540-54-9 1-[(2,3-dichlorophenyl)methyl]-6-(4-morpholinyl)-2-(trifluoromethyl)-1H-benzimidazole-4-carboxamide 
• 1372540-33-4 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxamide 
• 1372540-67-4 2-chloro-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid 
• 1372540-66-3 methyl 2-chloro-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylate 

Relevant articles and documents

A deuterated benzimidazole compound of preparation method and use thereof

The invention discloses a formula (I) indicated by the deuterium generation of benzene and imidazole compound or its pharmaceutically acceptable salt preparation method and use. The invention the deuterium generation of benzene and imidazole compound can

BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kβ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazoles compounds for treating cancer.

BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are sirtuin-modulating compounds of formula (II) The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Design of new bidentate ligands constructed of two Hoechst 33258 units for discrimination of the length of two A3T3 binding motifs

The aim of this study is to develop bidentate minor-groove binders that bind the double binding motifs cooperatively. The new bidentate ligands (1) have been designed by connecting two Hoechst 33258 units with a polyether linker for cooperative binding wi

ORGANIC COMPOUNDS

Compounds of formula (I) in free or salt form, where Y, R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the CXCR2 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

A convenient copper-catalyzed direct animation of nitroarenes with 9-alkylhydroxylamines

O-Alkylhydroxylamines, particularly O-methylhydroxylamine, aminate nitroarenes in the presence of a strong base and a copper catalyst to give aminonitroarenes in good yields, ortho- or para-Animation with respect to the nitro group takes place, and in some cases the ortho-aminated product is preferentially obtained. With 3-substituted nitrobenzenes where the substituent has a lone pair of electrons, preferential amination occurs at the 2-position to give the sterically most congested 3c-f, 14 and 22g.